Clinical Trials Logo

Nodal Marginal Zone Lymphoma clinical trials

View clinical trials related to Nodal Marginal Zone Lymphoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03697512 Active, not recruiting - Clinical trials for Splenic Marginal Zone Lymphoma

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

MALIBU
Start date: September 27, 2019
Phase: Phase 2
Study type: Interventional

Single-arm, phase II clinical trial of patients with Extranodal Marginal Zone Lymphoma (EMZL). It is planned to recruit 130 patients. Additional patients with Splenic Marginal Zone Lymphoma (SMZL), up to 30, and Nodal Marginal Zone Lymphoma (NMZL), up to 15, will be included in the trial in order to preliminary explore the clinical activity and safety of the combination treatment proposed. The study primary endpoints will be analysed on the EMZL population. Outcome of patients with SMZL and NMZL will be analysed and reported separately